North America Disease-Modifying Antirheumatic Drugs Market Size, Share, and Growth Forecast 2026 - 2033

The North America disease-modifying antirheumatic drugs market size is expected to be valued at US$ 14.5 billion in 2026 and projected to reach US$ 22.2 billion by 2033, growing at a CAGR of 6.3% between 2026 and 2033.

Growth is primarily driven by the rising burden of autoimmune and inflammatory joint disorders across the region, coupled with expanding access to advanced biologic and targeted synthetic therapies. According to the Centers for Disease Control and Prevention (CDC), nearly 58.5 million adults in the U.S. live with some form of diagnosed arthritis, sustaining consistent demand for long-term disease-modifying regimens. Continued clinical investment by innovators such as AbbVie Inc. and Pfizer Inc. is reinforcing this steady upward trajectory.

Growth Drivers - Rising Prevalence of Rheumatoid Arthritis and Autoimmune Joint Disorders

The escalating incidence of rheumatoid arthritis and related autoimmune conditions across North America remains the foremost catalyst propelling the Disease-Modifying Antirheumatic Drugs market forward. The Arthritis Foundation estimates that rheumatoid arthritis affects approximately 1.3 million adults in the U.S. alone, with women disproportionately impacted at nearly three times the rate of men. This growing patient pool, combined with earlier diagnosis enabled by improved serological testing and heightened physician awareness, is translating into greater prescription volumes for both conventional and biologic therapies.

Additionally, an aging population base, with the U.S. Census Bureau projecting that adults aged 65 and above will exceed 73 million by 2030, is further amplifying the addressable patient population, as arthritis prevalence rises sharply with advancing age.

Rapid Expansion of Biologic and Targeted Synthetic Therapy Pipelines

Sustained pharmaceutical innovation in biologic and targeted synthetic drug classes is significantly strengthening treatment efficacy and expanding the therapeutic arsenal available to rheumatologists. The U.S. Food and Drug Administration (FDA) has approved multiple novel Janus kinase (JAK) inhibitors and interleukin-targeting biologics over the past several years, offering patients alternatives when conventional synthetic DMARDs prove insufficient. Companies including Johnson & Johnson, Amgen Inc., and Eli Lilly and Company continue to expand indications for their flagship biologics into psoriatic arthritis and axial spondyloarthritis, broadening eligible patient segments. This continuous pipeline activity, supported by favorable clinical trial outcomes and accelerated regulatory pathways, is reinforcing physician confidence in advanced DMARD regimens and is expected to sustain strong prescription growth for newer drug classes through the forecast period.

Restraints - High Treatment Costs and Reimbursement Constraints

The substantial cost burden associated with biologic DMARDs continues to restrict broader patient access across North America. Annual treatment costs for biologic therapies can exceed US$ 30,000 to US$ 60,000 per patient, placing considerable strain on both public and private insurance frameworks. Prior authorization requirements imposed by major U.S. health insurers often delay treatment initiation, discouraging early intervention. Although patient assistance programs sponsored by manufacturers partially offset out-of-pocket expenses, high co-payments and step-therapy protocols remain persistent barriers, particularly for uninsured or underinsured populations, thereby moderating the pace of biologic DMARD adoption despite strong clinical demand.

Safety Concerns and Risk of Immunosuppression-Related Complications

Long-term use of Disease-Modifying Antirheumatic Drugs, particularly biologics and targeted synthetic agents, carries an elevated risk of serious infections, malignancies, and cardiovascular events due to sustained immune suppression. The FDA has mandated boxed warnings on several JAK inhibitors following post-marketing surveillance data linking them to increased risk of blood clots and major adverse cardiac events in select patient populations. Such safety signals have prompted more conservative prescribing practices among rheumatologists, especially for elderly patients or those with pre-existing comorbidities, and have contributed to slower uptake of certain targeted synthetic DMARDs despite their demonstrated efficacy advantages over older treatment regimens.

Opportunities - Accelerating Biosimilar Penetration Across Biologic DMARD Portfolios

The expiration of patents covering several blockbuster biologic DMARDs is creating substantial opportunities for biosimilar developers to capture cost-sensitive market share. Companies such as Celltrion Inc. and other biosimilar manufacturers have already launched multiple adalimumab and infliximab biosimilars across the U.S., following favorable interchangeability designations from the FDA. These lower-cost alternatives are enabling payers to expand formulary access while reducing overall treatment expenditure, particularly benefiting patients enrolled in employer-sponsored and government insurance plans such as Medicare.

As additional biologics lose exclusivity through 2030, industry stakeholders anticipate accelerated biosimilar competition, creating a significant growth avenue for manufacturers capable of scaling production, securing favorable payer contracts, and demonstrating robust real-world clinical equivalence to originator biologics.

Growing Adoption of Oral Targeted Synthetic DMARDs and Personalized Medicine

The rising preference for convenient, self-administered oral therapies is opening new growth avenues for targeted synthetic DMARDs, particularly JAK inhibitors, which eliminate the need for infusion center visits or injection training. Pharmaceutical developers including AbbVie Inc. and Pfizer Inc. are investing heavily in expanding indications for their oral franchises into juvenile idiopathic arthritis and axial spondyloarthritis, broadening the eligible patient base. Parallel advancements in pharmacogenomics and biomarker-driven treatment selection are enabling rheumatologists to better match patients to therapies most likely to achieve remission, reducing costly trial-and-error prescribing. This shift toward precision rheumatology, supported by growing real-world evidence databases, presents a compelling opportunity for companies to differentiate through companion diagnostics and outcome-based contracting models with payers.

Drug Class Analysis

Biologic DMARDs (bDMARDs) commanded the dominant share of the North America Disease-Modifying Antirheumatic Drugs market, accounting for approximately 64% of total revenue in 2026. This leadership stems from their superior efficacy in achieving disease remission among patients who fail to respond adequately to conventional synthetic DMARDs, alongside broad physician familiarity built over more than two decades of clinical use.

Tumor necrosis factor (TNF) inhibitors and interleukin inhibitors, marketed by companies such as AbbVie Inc., Amgen Inc., and Johnson & Johnson, remain the most widely prescribed biologic classes across rheumatoid arthritis and psoriatic arthritis indications. Expanding biosimilar availability has further reinforced biologic DMARD utilization by improving affordability, while robust long-term safety and efficacy data continue to support their preferred positioning within treatment guidelines issued by the American College of Rheumatology.

Route of Administration Analysis

Subcutaneous injection remained the leading route of administration, capturing an estimated 46% share of the North America Disease-Modifying Antirheumatic Drugs market in 2026. The dominance of this segment is closely tied to the widespread availability of self-administered biologic formulations, such as pre-filled pens and auto-injectors, which allow patients to manage chronic rheumatic conditions at home without frequent clinic visits. This convenience factor has been a key driver behind strong patient adherence rates, particularly for maintenance therapy in rheumatoid arthritis and psoriatic arthritis.

Manufacturers including UCB S.A. and Novartis AG have continued to prioritize subcutaneous formulation development, supported by device engineering advancements that reduce injection-site discomfort, thereby reinforcing this segment's continued market leadership through the forecast period.

North America Disease-Modifying Antirheumatic Drugs Market Trends and Insights

North America’s Disease-Modifying Antirheumatic Drugs market is supported by advanced healthcare infrastructure, high biologic adoption, established rheumatology networks, and favorable reimbursement frameworks. Increasing adoption of targeted synthetic and biologic DMARDs is improving treatment options for patients with rheumatoid arthritis and other autoimmune conditions. Growing biosimilar penetration is also contributing to improved affordability and broader access to advanced therapies.

In the U.S., continued FDA approvals and strong specialty pharmacy infrastructure are supporting market expansion, while Canada is benefiting from expanding public drug coverage and biosimilar adoption. Increasing diagnosis rates, treatment initiation, and healthcare spending are expected to sustain regional growth through 2033.

U.S. Disease-Modifying Antirheumatic Drugs Market Size

The U.S. accounted for approximately 88% of the North America Disease-Modifying Antirheumatic Drugs market in 2026, supported by its large patient population, advanced healthcare infrastructure, and extensive availability of biologic and targeted therapies.

High diagnosis and treatment rates for rheumatoid arthritis are generating substantial demand for conventional, biologic, and targeted synthetic DMARDs. Medicare, Medicaid, and commercial insurance programs provide coverage for many advanced therapies, although reimbursement requirements and treatment costs remain important considerations. The country’s established specialty pharmacy network, strong rheumatology infrastructure, and continued introduction of innovative therapies are further supporting market development. Increasing biosimilar availability is also expected to improve affordability and expand patient access through 2033.

Canada Disease-Modifying Antirheumatic Drugs Market Size

Canada is expected to represent the fastest-growing market in North America for Disease-Modifying Antirheumatic Drugs, supported by expanding access to advanced therapies and increasing adoption of biosimilars. Provincial public drug plans continue to influence treatment accessibility, while growing availability of lower-cost biosimilar alternatives is improving affordability for patients and healthcare systems. Rising awareness and diagnosis of rheumatoid arthritis are also supporting demand for DMARD therapies.

Health Canada’s regulatory environment and increasing use of biosimilar treatment options are encouraging broader adoption across the country. Continued investment in rheumatology services, improvements in treatment pathways, and expanding access to biologic therapies are expected to support above-average market growth through 2033.

The North America Disease-Modifying Antirheumatic Drugs market exhibits a moderately consolidated competitive structure, with a handful of established biopharmaceutical leaders such as AbbVie Inc., Johnson & Johnson, Pfizer Inc., and Amgen Inc. commanding a substantial share of biologic DMARD revenue. Competitive strategies center heavily on lifecycle management through label expansions, next-generation formulation development, and strategic collaborations with biosimilar manufacturers.

Companies are increasingly differentiating through patient support ecosystems, digital adherence tools, and outcome-based payer contracts rather than price alone. Meanwhile, biosimilar entrants such as Celltrion Inc. are reshaping competitive dynamics by intensifying price-based competition, compelling originator manufacturers to accelerate innovation pipelines toward novel mechanisms of action, including targeted synthetic and cytokine-modulating therapies.

Key Developments

• October 2026: AbbVie announced that RINVOQ® (upadacitinib) demonstrated superior efficacy compared with HUMIRA® (adalimumab) in achieving the primary endpoint in a head-to-head Phase III clinical study involving patients with rheumatoid arthritis who had experienced an inadequate response or treatment failure with their first tumor necrosis factor (TNF) inhibitor.
• September 2026: Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) approved TREMFYA® (guselkumab) for the treatment of pediatric patients with moderate-to-severe plaque psoriasis and active psoriatic arthritis. The approval marked the first and only interleukin-23 (IL-23) inhibitor authorized for use in both pediatric indications.